세포 분리 시장 : 제품별, 세포 유형별, 유래별, 방법별, 용도별, 최종사용자별, 지역별 - 세계 예측(-2031년)

The cell isolation market is expected to reach USD 7.97 billion in 2031 from USD 4.39 billion in 2026, at a CAGR of 12.7% during the forecast period. The market is primarily driven by the expansion of cell and gene therapy workflows, rising demand for immune cell isolation, growing adoption of single-cell analysis, and increasing use of automated and closed isolation systems. Technologies such as centrifugation-based isolation, magnetic-activated cell separation, fluorescence-activated cell sorting, microfluidic isolation, and filtration-based separation enable the enrichment and purification of specific cell populations, including immune cells, stem cells, circulating tumor cells, leukocytes, and primary cells. These technologies support applications across drug discovery, immunology research, cancer biology, regenerative medicine, biomarker discovery, and clinical research.

In addition, the growing demand for GMP-grade cell isolation products is driving adoption of validated kits, magnetic beads, single-use consumables, and closed-system platforms across clinical and manufacturing workflows. However, market growth continues to be challenged by the high cost of instruments and consumables, loss of cell viability and recovery during isolation, and difficulties in scaling research workflows to GMP manufacturing while balancing purity, yield, viability, and cost.

"The consumables segment is expected to grow at the highest CAGR during the forecast period"

The consumables segment is projected to grow at the highest CAGR in the cell isolation market, driven by the recurring use of magnetic beads, antibody-based isolation kits, density gradient media, buffers, cell strainers, columns, and single-use kits across research and clinical workflows. These products are widely used for immune cell isolation, stem cell enrichment, isolation of circulating tumor cells, primary cell separation, and sample preparation for downstream analysis. The growing use of cell isolation in cell and gene therapy development, single-cell analysis, immunology research, and cancer biology is increasing demand for high-purity, validated, and application-specific consumables.

"Human cells segment holds the largest share of the market"

The human cells segment accounts for the largest share of the cell isolation market, driven by the increasing use of human-derived immune cells, stem cells, circulating tumor cells, leukocytes, and primary cells in drug discovery, translational research, regenerative medicine, and clinical applications. Human cell isolation plays a critical role in immune profiling, biomarker discovery, cancer research, personalized medicine, and cell and gene therapy workflows. The growing demand for biologically relevant human cell models, along with the rising adoption of single-cell analysis and GMP-compatible cell processing, continues to strengthen this segment's position.

"The US is expected to grow at the highest CAGR during the forecast period"

The US is expected to grow at the highest CAGR in the cell isolation market due to its strong presence of leading life science companies, advanced biomedical research infrastructure, and high adoption of cell separation technologies across research and clinical settings. The rising use of cell isolation in cell and gene therapy development, immuno-oncology, stem cell research, single-cell analysis, and biomarker discovery is a key factor driving market growth. Technologies such as magnetic-activated cell separation, fluorescence-activated cell sorting, centrifugation-based isolation, and automated closed-system platforms are widely used across pharmaceutical companies, biotechnology firms, academic institutes, and clinical laboratories, further supporting demand.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side - 70% and Demand Side- 30%
• By Designation: Managers - 45%, CXOs and Directors - 30%, and Executives - 25%
• By Region: North America - 40%, Europe - 25%, Asia Pacific - 25%, Latin America - 5%, the Middle East & Africa - 5%

Danaher (US), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), BD (US), Sartorius AG (Germany), Agilent Technologies, Inc. (US), Bio-Rad Laboratories, Inc. (US), QIAGEN (Netherlands), F. Hoffmann-La Roche Ltd (Switzerland), Revvity (US), Corning Incorporated (US), Lonza (Switzerland), Bio-Techne (US), Terumo Corporation (Japan), Miltenyi Biotec (Germany), Takara Bio Inc. (Japan), GenScript (US), Sony Group Corporation (Japan), Alfa Laval (Sweden), Promega Corporation (US), Cell Signaling Technology, Inc. (US), MiCareo Inc. (Taiwan), Applied Cells, Inc. (US), STEMCELL Technologies (Canada), Creative Bioarray (US), Proteintech Group, Inc. (US), MagBio Genomics, Inc. (US), Akadeum Life Sciences (US), pluriSelect Life Science UG (haftungsbeschrankt) & Co. KG (Germany), and Invent Biotechnologies, Inc. (US) are some of the key companies offering cell isolation products.

Research Coverage

This research report categorizes the cell isolation market by product (consumables [reagents & kits {cell isolation reagents & kits, tissue dissociation reagents & kits, other reagents & kits}, media and sera, beads {magnetic beads, fluorescent beads}, and disposables] and instruments [centrifuges, cell sorters, magnetic-activated cell separator systems, filtration systems, and other instruments]), cell type (human cells [differentiated cells, stem cells] and animal cells), cell source (blood & blood-derived samples, adipose tissue, bone marrow, cord blood/embryonic stem cells, and other cell sources), technique (centrifugation-based cell isolation, surface marker-based cell isolation, filtration-based cell isolation, and microfluidics & label-free cell isolation), application (research applications [biomolecule isolation, cancer research, stem cell research, regenerative medicine, and other research applications], drug discovery and development, in vitro diagnostics, CGT manufacturing), end user (pharmaceutical & biotechnology companies, academic & research institutes, biopharmaceutical companies, hospitals & diagnostic laboratories, and other end users), and region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa).

The report's scope encompasses detailed information about the primary factors, including drivers, restraints, challenges, and opportunities, that influence the growth of the cell isolation market. A comprehensive analysis of key industry players has been conducted to provide insights into their business overviews, product portfolios, key strategies, new product launches, acquisitions, and recent developments in the cell isolation market. This report also includes a competitive analysis of emerging startups in the cell isolation industry ecosystem.

Key Benefits of Buying the Report

The report will assist market leaders and new entrants by providing revenue estimates for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their businesses effectively and develop suitable go-to-market strategies. This report will enable stakeholders to grasp the market's pulse and offer information on key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

• Analysis of key drivers (expansion of cell and gene therapy workflows, rising demand for immune cell isolation, growing adoption of single-cell analysis, shift toward automated and closed isolation systems), restraints (high cost of instruments and consumables, loss of cell viability and recovery during isolation), opportunities (growing demand for GMP-grade cell isolation products, adoption of microfluidic and label-free isolation technologies), and challenges (scaling research workflows to GMP manufacturing, balancing purity, yield, viability, and cost) influencing the market growth
• Product Development/Innovation: Detailed insights into newly launched products and innovations in the cell isolation market
• Market Development: Comprehensive information about lucrative markets and analysis of the market across varied regions
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the cell isolation market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and products of leading players, Danaher (US), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), BD (US), Sartorius AG (Germany), Agilent Technologies, Inc. (US), Bio-Rad Laboratories, Inc. (US), QIAGEN (Netherlands), F. Hoffmann-La Roche Ltd (Switzerland), Revvity (US), and Corning Incorporated (US), among others, for the cell isolation market

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION & REGIONS COVERED
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

• 2.1 MARKET HIGHLIGHTS & KEY INSIGHTS
• 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
• 2.3 DISRUPTIVE TRENDS IN CELL ISOLATION MARKET
• 2.4 HIGH-GROWTH SEGMENTS
• 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

• 3.1 CELL ISOLATION MARKET OVERVIEW
• 3.2 NORTH AMERICA: CELL ISOLATION MARKET, BY PRODUCT AND COUNTRY
• 3.3 CELL ISOLATION MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 3.4 CELL ISOLATION MARKET SHARE, BY PRODUCT, 2026 VS. 2031 (%)

4 MARKET OVERVIEW

• 4.1 INTRODUCTION
• 4.2 MARKET DYNAMICS
  • 4.2.1 DRIVERS
    • 4.2.1.1 Expansion of cell and gene therapy workflows
    • 4.2.1.2 Rising demand for immune cell isolation
    • 4.2.1.3 Growing adoption of single-cell analysis
    • 4.2.1.4 Shift toward automated and closed isolation systems
  • 4.2.2 RESTRAINTS
    • 4.2.2.1 High cost of instruments and consumables
    • 4.2.2.2 Loss of cell viability and recovery during isolation
  • 4.2.3 OPPORTUNITIES
    • 4.2.3.1 Growing demand for GMP-grade cell isolation products
    • 4.2.3.2 Adoption of microfluidic and label-free isolation technologies
  • 4.2.4 CHALLENGES
    • 4.2.4.1 Scaling research workflows to GMP manufacturing
    • 4.2.4.2 Balancing purity, yield, viability, and cost
• 4.3 UNMET NEEDS & WHITE SPACES
• 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
• 4.5 STRATEGIC MOVIES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS

• 5.1 PORTER'S FIVE FORCES ANALYSIS
  • 5.1.1 INTENSITY OF COMPETITIVE RIVALRY
  • 5.1.2 BARGAINING POWER OF SUPPLIERS
  • 5.1.3 BARGAINING POWER OF BUYERS
  • 5.1.4 THREAT OF SUBSTITUTES
  • 5.1.5 THREAT OF NEW ENTRANTS
• 5.2 MACROECONOMIC OUTLOOK
  • 5.2.1 INTRODUCTION
  • 5.2.2 GDP TRENDS & FORECAST
  • 5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY
  • 5.2.4 TRENDS IN GLOBAL BIOTECH INDUSTRY
• 5.3 VALUE CHAIN ANALYSIS
• 5.4 ECOSYSTEM ANALYSIS
  • 5.4.1 ROLE OF PLAYERS IN ECOSYSTEM
• 5.5 PRICING ANALYSIS
  • 5.5.1 AVERAGE SELLING PRICE TREND OF CELL ISOLATION INSTRUMENTS, BY TYPE, 2023-2025
  • 5.5.2 AVERAGE SELLING PRICE TREND OF CELL ISOLATION CONSUMABLES, BY TYPE, 2023-2025
  • 5.5.3 AVERAGE SELLING PRICE TREND OF CELL ISOLATION INSTRUMENTS, BY REGION, 2023-2025
  • 5.5.4 AVERAGE SELLING PRICE TREND OF CELL ISOLATION CONSUMABLES, BY REGION, 2023-2025
• 5.6 TRADE ANALYSIS
  • 5.6.1 IMPORT SCENARIO (HS CODE 3822.00)
  • 5.6.2 EXPORT SCENARIO (HS CODE 3822.00)
• 5.7 KEY CONFERENCES & EVENTS, 2026-2027
• 5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.9 INVESTMENT & FUNDING SCENARIO
• 5.10 CASE STUDY ANALYSIS
  • 5.10.1 MICROFLUIDIC CELL SORTING IMPROVES CAR-T STARTING MATERIAL QUALITY
  • 5.10.2 CLOSED-SYSTEM CELL ENRICHMENT SUPPORTS NK CELL MANUFACTURING
  • 5.10.3 MICROFLUIDIC ISOLATION ENHANCES CTC RECOVERY IN PANCREATIC CANCER
• 5.11 IMPACT OF 2025 US TARIFFS ON CELL ISOLATION MARKET
  • 5.11.1 INTRODUCTION
  • 5.11.2 KEY TARIFF RATES
  • 5.11.3 PRICE IMPACT ANALYSIS
  • 5.11.4 IMPACT ON COUNTRY/REGION
    • 5.11.4.1 US
    • 5.11.4.2 Europe
    • 5.11.4.3 Asia Pacific
  • 5.11.5 IMPACT ON END-USE INDUSTRIES
    • 5.11.5.1 Pharmaceutical & biotechnology companies
    • 5.11.5.2 Academic & research institutes
    • 5.11.5.3 Hospitals & diagnostic laboratories

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

• 6.1 TECHNOLOGY ANALYSIS
  • 6.1.1 KEY TECHNOLOGIES
    • 6.1.1.1 Centrifugation-based techniques
    • 6.1.1.2 Magnetic cell isolation
    • 6.1.1.3 Fluorescence-activated cell sorting
    • 6.1.1.4 Acoustofluidic cell isolation
    • 6.1.1.5 Filtration & size-based cell isolation
  • 6.1.2 COMPLEMENTARY TECHNOLOGIES
    • 6.1.2.1 Mass cytometry
    • 6.1.2.2 Cell imaging technologies
    • 6.1.2.3 AI-enabled image-based sorting
  • 6.1.3 ADJACENT TECHNOLOGIES
    • 6.1.3.1 Single-cell sequencing
    • 6.1.3.2 CRISPR & gene editing
    • 6.1.3.3 3D cell culture & organoids
• 6.2 TECHNOLOGY ROADMAP
• 6.3 PATENT ANALYSIS
  • 6.3.1 METHODOLOGY
  • 6.3.2 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE
  • 6.3.3 LIST OF KEY PATENTS
• 6.4 FUTURE APPLICATIONS
• 6.5 IMPACT OF AI/GEN AI ON CELL ISOLATION MARKET
  • 6.5.1 TOP USE CASES & MARKET POTENTIAL
  • 6.5.2 BEST PRACTICES IN AI-ENABLED CELL ISOLATION WORKFLOWS
  • 6.5.3 CASE STUDIES OF AI IMPLEMENTATION IN CELL ISOLATION MARKET
  • 6.5.4 INTERCONNECTED ADJACENT ECOSYSTEMS & IMPACT ON MARKET PLAYERS
  • 6.5.5 CLIENTS' READINESS TO ADOPT AI-INTEGRATED CELL ISOLATION TECHNOLOGIES

7 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

• 7.1 DECISION-MAKING PROCESS
• 7.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
  • 7.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 7.2.2 KEY BUYING CRITERIA, BY END USER
• 7.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
• 7.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES

8 SUSTAINABILITY & REGULATORY LANDSCAPE

• 8.1 REGIONAL REGULATIONS & COMPLIANCE
  • 8.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 8.1.2 INDUSTRY STANDARDS
    • 8.1.2.1 North America
    • 8.1.2.2 Europe
    • 8.1.2.3 Asia Pacific
    • 8.1.2.4 Rest of the world
• 8.2 SUSTAINABILITY INITIATIVES
• 8.3 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES
• 8.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS

9 CELL ISOLATION MARKET, BY PRODUCT

• 9.1 INTRODUCTION
• 9.2 CONSUMABLES
  • 9.2.1 REAGENTS & KITS
    • 9.2.1.1 Cell isolation reagents & kits
      • 9.2.1.1.1 Expansion of downstream single-cell genomics to drive market
    • 9.2.1.2 Tissue dissociation reagents & kits
      • 9.2.1.2.1 Influx of solid tumor oncology profiling and primary cell culture derivations to drive growth
    • 9.2.1.3 Other reagents & kits
  • 9.2.2 MEDIA & SERA
    • 9.2.2.1 Rising focus on viable, reproducible, and clinically compatible isolated cell workflows to fuel market
  • 9.2.3 BEADS
    • 9.2.3.1 Growing demand for beads in T-cell and stem cell isolation to drive market growth
  • 9.2.4 DISPOSABLES
    • 9.2.4.1 Growing government investments in research to aid market growth
• 9.3 INSTRUMENTS
  • 9.3.1 CENTRIFUGES
    • 9.3.1.1 Growing use in pharma-biotech industry to boost market
  • 9.3.2 CELL SORTERS
    • 9.3.2.1 Rise in cell-based research initiatives to augment growth
  • 9.3.3 MAGNETIC-ACTIVATED CELL SEPARATOR SYSTEMS
    • 9.3.3.1 Booming use in research for T-cell and stem cell isolation to drive market
  • 9.3.4 FILTRATION SYSTEMS
    • 9.3.4.1 Rising need to ensure Good Manufacturing Practice standards and regulations to boost market
  • 9.3.5 OTHER INSTRUMENTS

10 CELL ISOLATION MARKET, BY CELL TYPE

• 10.1 INTRODUCTION
• 10.2 HUMAN CELLS
  • 10.2.1 DIFFERENTIATED CELLS
    • 10.2.1.1 Rising use of mature human cell populations in translational research and drug development to fuel growth
  • 10.2.2 STEM CELLS
    • 10.2.2.1 Rise in grants and funding for stem cell research to drive market
• 10.3 ANIMAL CELLS
  • 10.3.1 GROWING INVESTMENTS FOR VACCINE AND DRUG DEVELOPMENT TO SUPPORT GROWTH

11 CELL ISOLATION MARKET, BY CELL SOURCE

• 11.1 INTRODUCTION
• 11.2 BLOOD & BLOOD-DERIVED SAMPLES
  • 11.2.1 GROWING USE OF IMMUNE CELL ISOLATION FROM BLOOD-DERIVED SAMPLES TO DRIVE MARKET
• 11.3 ADIPOSE TISSUE
  • 11.3.1 INCREASING APPLICATIONS IN CLINICAL STUDIES AND TRIALS TO DRIVE MARKET
• 11.4 BONE MARROW
  • 11.4.1 GROWING DEMAND FOR TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS TO AID GROWTH
• 11.5 CORD BLOOD/EMBRYONIC STEM CELLS
  • 11.5.1 GROWING USE OF STEM AND PROGENITOR CELL ISOLATION IN REGENERATIVE MEDICINE AND CELL THERAPY RESEARCH TO SUPPORT MARKET GROWTH
• 11.6 OTHER CELL SOURCES

12 CELL ISOLATION MARKET, BY TECHNIQUE

• 12.1 INTRODUCTION
• 12.2 CENTRIFUGATION-BASED CELL ISOLATION
  • 12.2.1 RISING DEMAND FOR SCALABLE, AUTOMATED, AND CLOSED CELL PREPARATION WORKFLOWS TO FUEL MARKET
• 12.3 SURFACE MARKER-BASED CELL ISOLATION
  • 12.3.1 GROWING NEED FOR MARKER-SPECIFIC AND HIGH-PURITY CELL POPULATIONS TO PROPEL MARKET
• 12.4 FILTRATION-BASED CELL ISOLATION
  • 12.4.1 NEED FOR AFFORDABLE FILTRATION TECHNIQUE TO DRIVE MARKET
• 12.5 MICROFLUIDICS & LABEL-FREE CELL ISOLATION
  • 12.5.1 HIGH DEMAND FOR ONCOLOGY RESEARCH TO SUPPORT SEGMENTAL GROWTH

13 CELL ISOLATION MARKET, BY APPLICATION

• 13.1 INTRODUCTION
• 13.2 RESEARCH APPLICATIONS
  • 13.2.1 BIOMOLECULE ISOLATION
    • 13.2.1.1 Increasing demand for biopharmaceutical products to fuel market
  • 13.2.2 CANCER RESEARCH
    • 13.2.2.1 Precision oncology and rare tumor cell analysis to drive market
  • 13.2.3 STEM CELL RESEARCH
    • 13.2.3.1 Rising grants and funding for stem cell research to augment growth
  • 13.2.4 REGENERATIVE MEDICINE
    • 13.2.4.1 Expanding stem cell and translational therapy research to support market
  • 13.2.5 OTHER RESEARCH APPLICATIONS
• 13.3 DRUG DISCOVERY & DEVELOPMENT
  • 13.3.1 RISING ADOPTION OF CELL-BASED DRUG DISCOVERY AND PRECISION THERAPEUTICS TO PROPEL MARKET
• 13.4 IN VITRO DIAGNOSTICS
  • 13.4.1 RISING ADOPTION OF LIQUID BIOPSY AND PRECISION DIAGNOSTICS TO PROPEL MARKET
• 13.5 CGT MANUFACTURING
  • 13.5.1 EXPANSION OF GMP-COMPLIANT CGT MANUFACTURING CAPACITY TO PROPEL MARKET

14 CELL ISOLATION MARKET, BY END USER

• 14.1 INTRODUCTION
• 14.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 14.2.1 INCREASING INVESTMENTS BY KEY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO BOOST MARKET GROWTH
• 14.3 ACADEMIC & RESEARCH INSTITUTES
  • 14.3.1 HIGH GOVERNMENT FUNDING FOR EDUCATIONAL PURPOSES TO FUEL SEGMENT
• 14.4 HOSPITALS & DIAGNOSTIC LABORATORIES
  • 14.4.1 RISING DEMAND FOR ENRICHED CLINICAL CELL POPULATIONS IN ONCOLOGY AND HEMATOLOGY DIAGNOSTICS TO DRIVE MARKET
• 14.5 OTHER END USERS

15 CELL ISOLATION MARKET, BY REGION

• 15.1 INTRODUCTION
• 15.2 NORTH AMERICA
  • 15.2.1 US
    • 15.2.1.1 Strong biopharma R&D and advanced cell sorting adoption to drive market
  • 15.2.2 CANADA
    • 15.2.2.1 Expanding cell therapy manufacturing and regenerative medicine research to propel market
• 15.3 EUROPE
  • 15.3.1 GERMANY
    • 15.3.1.1 Strong cell & gene therapy translation and GMP-ready automated cell processing to aid market growth
  • 15.3.2 UK
    • 15.3.2.1 Expanding advanced therapy infrastructure and GMP-compatible cell processing workflows to drive market
  • 15.3.3 FRANCE
    • 15.3.3.1 Expanding biotherapy research and cell & gene therapy infrastructure to drive market
  • 15.3.4 ITALY
    • 15.3.4.1 Expanding advanced therapy trials and ex vivo gene therapy capabilities to drive market
  • 15.3.5 SPAIN
    • 15.3.5.1 Hospital-based CAR-T manufacturing and GMP-compatible cell processing workflows to aid growth
  • 15.3.6 REST OF EUROPE
• 15.4 ASIA PACIFIC
  • 15.4.1 CHINA
    • 15.4.1.1 Expanding cell therapy pipelines and regenerative medicine commercialization to boost market
  • 15.4.2 JAPAN
    • 15.4.2.1 iPSC research leadership, regenerative medicine commercialization, and domestic cell therapy manufacturing expansion to drive market growth
  • 15.4.3 INDIA
    • 15.4.3.1 BioE3-led biomanufacturing and translational research expansion propel market
  • 15.4.4 AUSTRALIA
    • 15.4.4.1 Hospital-linked GMP cell therapy capacity, regenerative medicine trials, and translational research infrastructure to fuel market
  • 15.4.5 SOUTH KOREA
    • 15.4.5.1 Bioprocessing infrastructure expansion and regenerative medicine focus to support market growth
  • 15.4.6 REST OF ASIA PACIFIC
• 15.5 LATIN AMERICA
  • 15.5.1 BRAZIL
    • 15.5.1.1 Advanced therapy regulation and oncology research strength to drive market
  • 15.5.2 MEXICO
    • 15.5.2.1 Regulatory strengthening and pharmaceutical infrastructure growth to support the market
  • 15.5.3 REST OF LATIN AMERICA
• 15.6 MIDDLE EAST
  • 15.6.1 GCC COUNTRIES
    • 15.6.1.1 Saudi Arabia
      • 15.6.1.1.1 Local advanced therapy manufacturing and precision medicine investment to boost market
    • 15.6.1.2 UAE
      • 15.6.1.2.1 Stem cell research infrastructure and regenerative medicine standards to aid market growth
    • 15.6.1.3 Rest of GCC Countries
  • 15.6.2 REST OF MIDDLE EAST
• 15.7 AFRICA
  • 15.7.1 POPULATION-SPECIFIC ONCOLOGY RESEARCH AND INFECTIOUS DISEASE STUDIES TO PROPEL MARKET

16 COMPETITIVE LANDSCAPE

• 16.1 OVERVIEW
• 16.2 KEY PLAYER STRATEGY/RIGHT TO WIN, JANUARY 2023-APRIL 2026
  • 16.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CELL ISOLATION MARKET, JANUARY 2023-APRIL 2026
• 16.3 REVENUE ANALYSIS, 2021-2025
• 16.4 MARKET SHARE ANALYSIS, 2025
• 16.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
  • 16.5.1 STARS
  • 16.5.2 EMERGING LEADERS
  • 16.5.3 PERVASIVE PLAYERS
  • 16.5.4 PARTICIPANTS
  • 16.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
    • 16.5.5.1 Company footprint
    • 16.5.5.2 Region footprint
    • 16.5.5.3 Product footprint
    • 16.5.5.4 Cell type footprint
    • 16.5.5.5 End-user footprint
• 16.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
  • 16.6.1 PROGRESSIVE COMPANIES
  • 16.6.2 RESPONSIVE COMPANIES
  • 16.6.3 DYNAMIC COMPANIES
  • 16.6.4 STARTING BLOCKS
  • 16.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
    • 16.6.5.1 Detailed list of key startup/SME players
    • 16.6.5.2 Competitive benchmarking of startups/SMEs
• 16.7 COMPANY VALUATION & FINANCIAL METRICS
  • 16.7.1 COMPANY VALUATION
  • 16.7.2 FINANCIAL METRICS
• 16.8 BRAND/PRODUCT COMPARISON
• 16.9 COMPETITIVE SCENARIO
  • 16.9.1 PRODUCT LAUNCHES
  • 16.9.2 DEALS
  • 16.9.3 EXPANSIONS

17 COMPANY PROFILES

• 17.1 KEY PLAYERS
  • 17.1.1 DANAHER CORPORATION
    • 17.1.1.1 Business overview
    • 17.1.1.2 Products offered
    • 17.1.1.3 Recent developments
      • 17.1.1.3.1 Deals
    • 17.1.1.4 MnM view
      • 17.1.1.4.1 Key strengths
      • 17.1.1.4.2 Strategic choices
      • 17.1.1.4.3 Weaknesses & competitive threats
  • 17.1.2 MERCK KGAA
    • 17.1.2.1 Business overview
    • 17.1.2.2 Products offered
    • 17.1.2.3 Recent developments
      • 17.1.2.3.1 Deals
      • 17.1.2.3.2 Expansions
    • 17.1.2.4 MnM view
      • 17.1.2.4.1 Key strengths
      • 17.1.2.4.2 Strategic choices
      • 17.1.2.4.3 Weaknesses & competitive threats
  • 17.1.3 THERMO FISHER SCIENTIFIC INC.
    • 17.1.3.1 Business overview
    • 17.1.3.2 Products offered
    • 17.1.3.3 Recent developments
      • 17.1.3.3.1 Product launches
      • 17.1.3.3.2 Deals
      • 17.1.3.3.3 Expansions
    • 17.1.3.4 MnM view
      • 17.1.3.4.1 Key strengths
      • 17.1.3.4.2 Strategic choices
      • 17.1.3.4.3 Weaknesses & competitive threats
  • 17.1.4 BECTON, DICKINSON AND COMPANY
    • 17.1.4.1 Business overview
    • 17.1.4.2 Products offered
    • 17.1.4.3 Recent developments
      • 17.1.4.3.1 Product launches
      • 17.1.4.3.2 Deals
    • 17.1.4.4 MnM view
      • 17.1.4.4.1 Key strengths
      • 17.1.4.4.2 Strategic choices
      • 17.1.4.4.3 Weaknesses & competitive threats
  • 17.1.5 AGILENT TECHNOLOGIES, INC.
    • 17.1.5.1 Business overview
    • 17.1.5.2 Products offered
    • 17.1.5.3 Recent developments
      • 17.1.5.3.1 Deals
    • 17.1.5.4 MnM view
      • 17.1.5.4.1 Key strengths
      • 17.1.5.4.2 Strategic choices
      • 17.1.5.4.3 Weaknesses & competitive threats
  • 17.1.6 SARTORIUS AG
    • 17.1.6.1 Business overview
    • 17.1.6.2 Products offered
  • 17.1.7 BIO-RAD LABORATORIES, INC.
    • 17.1.7.1 Business overview
    • 17.1.7.2 Products offered
    • 17.1.7.3 Recent developments
      • 17.1.7.3.1 Product launches
  • 17.1.8 QIAGEN
    • 17.1.8.1 Business overview
    • 17.1.8.2 Products offered
    • 17.1.8.3 Recent developments
      • 17.1.8.3.1 Deals
  • 17.1.9 F. HOFFMANN-LA ROCHE LTD.
    • 17.1.9.1 Business overview
    • 17.1.9.2 Products offered
    • 17.1.9.3 Recent developments
      • 17.1.9.3.1 Expansions
  • 17.1.10 REVVITY
    • 17.1.10.1 Business overview
    • 17.1.10.2 Products offered
  • 17.1.11 CORNING INCORPORATED
    • 17.1.11.1 Business overview
    • 17.1.11.2 Products offered
  • 17.1.12 LONZA
    • 17.1.12.1 Business overview
    • 17.1.12.2 Products offered
  • 17.1.13 BIO-TECHNE
    • 17.1.13.1 Business overview
    • 17.1.13.2 Products offered
  • 17.1.14 TERUMO CORPORATION
    • 17.1.14.1 Business overview
    • 17.1.14.2 Products offered
  • 17.1.15 MILTENYI BIOTEC
    • 17.1.15.1 Business overview
    • 17.1.15.2 Products offered
  • 17.1.16 TAKARA BIO INC.
    • 17.1.16.1 Business overview
    • 17.1.16.2 Products offered
  • 17.1.17 GENSCRIPT
    • 17.1.17.1 Business overview
    • 17.1.17.2 Products offered
    • 17.1.17.3 Recent developments
      • 17.1.17.3.1 Deals
  • 17.1.18 SONY CORPORATION
    • 17.1.18.1 Business overview
    • 17.1.18.2 Products offered
  • 17.1.19 ALFA LAVAL
    • 17.1.19.1 Business overview
    • 17.1.19.2 Products offered
    • 17.1.19.3 Recent developments
      • 17.1.19.3.1 Product launches
      • 17.1.19.3.2 Deals
• 17.2 OTHER PLAYERS
  • 17.2.1 PROMEGA CORPORATION
  • 17.2.2 CELL SIGNALING TECHNOLOGY, INC.
  • 17.2.3 MICAREO INC.
  • 17.2.4 APPLIED CELLS, INC.
  • 17.2.5 STEMCELL TECHNOLOGIES
  • 17.2.6 CREATIVE BIOARRAY
  • 17.2.7 PROTEINTECH GROUP, INC.
  • 17.2.8 MAGBIO GENOMICS, INC.
  • 17.2.9 AKADEUM LIFE SCIENCES
  • 17.2.10 PLURISELECT LIFE SCIENCE UG (HAFTUNGSBESCHRANKT) & CO. KG
  • 17.2.11 INVENT BIOTECHNOLOGIES, INC.

18 RESEARCH METHODOLOGY

• 18.1 RESEARCH DATA
  • 18.1.1 SECONDARY DATA
    • 18.1.1.1 Key data from secondary sources
  • 18.1.2 PRIMARY DATA
    • 18.1.2.1 Key data from primary sources
    • 18.1.2.2 Key primary participants
    • 18.1.2.3 Breakdown of primary interviews
    • 18.1.2.4 Key industry insights
• 18.2 MARKET SIZE ESTIMATION
  • 18.2.1 GLOBAL CELL ISOLATION MARKET ESTIMATION, 2025
  • 18.2.2 SEGMENTAL MARKET SIZE ESTIMATION
• 18.3 MARKET GROWTH RATE PROJECTIONS
• 18.4 DATA TRIANGULATION
• 18.5 FACTOR ANALYSIS
• 18.6 RESEARCH ASSUMPTIONS
• 18.7 RESEARCH LIMITATIONS & RISK ASSESSMENT

19 APPENDIX

• 19.1 DISCUSSION GUIDE
• 19.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 19.3 CUSTOMIZATION OPTIONS
• 19.4 RELATED REPORTS
• 19.5 AUTHOR DETAILS